4. Friedman L. S., Ostermeyer E A, Lynch E D, Szabo C I, Anderson L A, Dowd P, Lee M K, Rowell S E, Boyd J and King M C. The

參考文獻

1. Greenlee R. T., Murray T, Bolden S and Wingo P A. Cancer statistics, 2000. CA: a cancer journal for clinicians.

2000;50(1):7-33.

2. Benichou J, Byrne C, Gail M, Harris A, Edwards BK, Blot WJ, 1996 Cancer Rates and Risks, 4th, 120-123.

3. Harrison L. B., Chadha M, Hill R J, Hu K and Shasha D. Impact of tumor hypoxia and anemia on radiation therapy outcomes. The oncologist. 2002;7(6):492-508.

4. Friedman L. S., Ostermeyer E A, Lynch E D, Szabo C I, Anderson L A, Dowd P, Lee M K, Rowell S E, Boyd J and King M C. The

search for BRCA1. Cancer research. 1994;54(24):6374-6382.

5. Wooster R., Neuhausen S L, Mangion J, Quirk Y, Ford D, Collins N, Nguyen K, Seal S, Tran T and Averill D. Localization of a breast cancer susceptibility gene, BRCA2, to chromosome 13q12-13.

Science. 1994;265(5181):2088-2090.

6. Fisher B., Anderson S, Bryant J, Margolese R G, Deutsch M, Fisher E R, Jeong J H and Wolmark N. Twenty-year follow-up of a

randomized trial comparing total mastectomy, lumpectomy, and lumpectomy plus irradiation for the treatment of invasive breast cancer. The New England journal of medicine.

2002;347(16):1233-1241.

7. Fisher B., Redmond C, Fisher E R, Bauer M, Wolmark N,

Wickerham D L, Deutsch M, Montague E, Margolese R and Foster

R. Ten-year results of a randomized clinical trial comparing radical

mastectomy and total mastectomy with or without radiation. The

New England journal of medicine. 1985;312(11):674-681.

8. Fisher B., Redmond C, Poisson R, Margolese R, Wolmark N, Wickerham L, Fisher E, Deutsch M, Caplan R and Pilch Y.

Eight-year results of a randomized clinical trial comparing total mastectomy and lumpectomy with or without irradiation in the treatment of breast cancer. The New England journal of medicine.

1989;320(13):822-828.

9. Fisher B., Anderson S, Redmond C K, Wolmark N, Wickerham D L and Cronin W M. Reanalysis and results after 12 years of follow-up in a randomized clinical trial comparing total mastectomy with lumpectomy with or without irradiation in the treatment of breast cancer. The New England journal of medicine.

1995;333(22):1456-1461.

10. Fisher B., Jeong J H, Anderson S, Bryant J, Fisher E R and Wolmark N. Twenty-five-year follow-up of a randomized trial comparing radical mastectomy, total mastectomy, and total mastectomy followed by irradiation. The New England journal of medicine.

2002;347(8):567-575.

11. 林昭庚 2002 中西醫病名對照大辭典 人民衛生出版社 第一卷 457-458

12. 孫貽安 劉曉菲 中醫對乳腺癌的認識及術後治療原則 第 23 卷 第 1 期 2005 年 1 月 180-182

13. 周維順 郭勇 謝長生 略論乳腺癌的診治原則 浙江中醫學院學 報 1995 19(4):3-4

14. 唐新.顧乃強診治乳癌經驗談 上海中醫藥雜誌 1997,31(8):28

15. 單敬文.辨証治療乳腺癌的體會 浙江中醫雜誌 1997,32(3):114

16. 乳病薈萃 中華中醫外科學會乳腺病專業委員會編 世界圖書出

版西安公司 1995,79

17. 古今名醫臨証金鑑•腫瘤卷 北京 中國中醫藥出版社 1999, 389

∼391

18. 張佩秋 乳腺癌的中醫診治概況 中國中醫藥信息雜誌 1996 年第 3 卷 第 3 期 27-28

19. 癌症腫瘤醫論醫話精選 樂群文化事業公司 楊維傑主編 1989 年 576-577

20. 顧乃強 顧伯華教授治療乳房病經驗介紹 乳病薈萃 中華中醫外 科學會乳腺病專業委員會編 世界圖書出版西安公司 1995 77-80

21. 癌症腫瘤醫論醫話精選 樂群文化事業公司 楊維傑主編 1989 年 176

22. Little J. B. Radiation carcinogenesis. Carcinogenesis.

2000;21(3):397-404.

23. Higuchi M. and Aggarwal B B. Differential roles of two types of the TNF receptor in TNF-induced cytotoxicity, DNA fragmentation, and differentiation. Journal of immunology (Baltimore, Md. : 1950).

1994;152(8):4017-4025.

24. Masunaga S., Ono K and Abe M. The detection and modification of the hypoxic fraction in quiescent cell populations in murine solid tumours. The British journal of radiology. 1993;66(790):918-926.

25. Lawrence T. S., Blackstock A W and McGinn C. The mechanism of action of radiosensitization of conventional chemotherapeutic agents.

Seminars in radiation oncology. 2003;13(1):13-21.

26. Carmichael J. and Hickson I D. Keynote address: mechanisms of

cellular resistance to cytotoxic drugs and X-irradiation. International

journal of radiation oncology, biology, physics. 1991;20(2):197-202.

27. Fertil B. and Malaise E P. Intrinsic radiosensitivity of human cell lines is correlated with radioresponsiveness of human tumors:

analysis of 101 published survival curves. International journal of radiation oncology, biology, physics. 1985;11(9):1699-1707.

28. Peters L. J., Withers H R, Thames H D,Jr and Fletcher G H. Tumor radioresistance in clinical radiotherapy. International journal of radiation oncology, biology, physics. 1982;8(1):101-108.

29. Carmichael J. and Hickson I D. Keynote address: mechanisms of cellular resistance to cytotoxic drugs and X-irradiation. International journal of radiation oncology, biology, physics. 1991;20(2):197-202.

30. Coleman C. N., Bump E A and Kramer R A. Chemical modifiers of cancer treatment. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 1988;6(4):709-733.

31. Coleman C. N. Hypoxia in tumors: a paradigm for the approach to biochemical and physiologic heterogeneity. Journal of the National Cancer Institute. 1988;80(5):310-317.

32. Varnes M. E., Dethlefsen L A and Biaglow J E. The effect of pH on potentially lethal damage recovery in A549 cells. Radiation research.

1986;108(1):80-90.

33. Hill R. P. Tumor progression: potential role of unstable genomic changes. Cancer and metastasis reviews. 1990;9(2):137-147.

34. Dische S. A review of hypoxic cell radiosensitization. International journal of radiation oncology, biology, physics. 1991;20(1):147-152.

35. Boag J. W. and Adams G E. Transient Chemical Species formed by Radiation. Fundamental Cancer Research. 1964;64-85.

36. Hirst D. G. Oxygen delivery to tumors. International journal of

radiation oncology, biology, physics. 1986;12(8):1271-1277.

37. Davis JC, Hunt TK. The Role of Oxygen. 1988;17-51.

38. McMillan T., Calhoun K H, Mader J T, Stiernberg C M and Rajaraman S. The effect of hyperbaric oxygen therapy of oral mucosal carcinoma. The Laryngoscope. 1989;99(3):241-244.

39. Marx R. E., Ehler W J, Tayapongsak P and Pierce L W. Relationship of oxygen dose to angiogenesis induction in irradiated tissue.

American Journal of Surgery. 1990;160(5):519-524.

40. Alagoz T., Buller R E, Anderson B, Terrell K L, Squatrito R C, Niemann T H, Tatman D J and Jebson P. Evaluation of hyperbaric oxygen as a chemosensitizer in the treatment of epithelial ovarian cancer in xenografts in mice. Cancer. 1995;75(9):2313-2322.

41. Plenk H. P. Radiation therapy under hyperbaric oxygen.

International journal of radiation oncology, biology, physics.

1977;2(7-8):819-820.

42. Henk, J. M. 5th International Hyperbaric Congress Proceedings, Vol.

II. Vancouver, British Columbia. 1974. p.794.

43. Henk J. M. Late results of a trial of hyperbaric oxygen and

radiotherapy in head and neck cancer: a rationale for hypoxic cell sensitizers? International journal of radiation oncology, biology, physics. 1986;12(8):1339-1341.

44. Sealy R., Berry R J, Ryall R D, Mills E E and Sellars S L. The

treatment of carcinoma of the nasopharynx in hyperbaric oxygen: an outside assessment. International journal of radiation oncology, biology, physics. 1977;2(7-8):711-714.

45. Brady L. W., Plenk H P, Hanley J A, Glassburn J R, Kramer S and Parker R G. Hyperbaric oxygen therapy for carcinoma of the

cervix--stages IIB, IIIA, IIIB and IVA: results of a randomized study

by the Radiation Therapy Oncology Group. International journal of

radiation oncology, biology, physics. 1981;7(8):991-998.

46. Johnson R. Current concepts in cancer: updated cervix cancer.

Stages III and IV. Hyperbaric oxygen as a radiation sensitizer for carcinoma of the cervix. International journal of radiation oncology, biology, physics. 1979;5(11-12):2151-2155.

47. Dische S., Saunders M I and Warburton M F. Hemoglobin, radiation, morbidity and survival. International journal of radiation oncology, biology, physics. 1986;12(8):1335-1337.

48. Henk J. M. Does hyperbaric oxygen have a future in radiation therapy? International journal of radiation oncology, biology, physics. 1981;7(8):1125-1128.

49. Hong A., Rojas A and Dische S. Normobaric oxygen as a sensitizer of hypoxic tumor cells. International journal of radiation oncology, biology, physics. 1989;16(4):1097-1099.

50. Hirst D. G. Anemia: a problem or an opportunity in radiotherapy?

International journal of radiation oncology, biology, physics.

1986;12(11):2009-2017.

51. Dische S., Saunders M I and Warburton M F. Hemoglobin, radiation, morbidity and survival. International journal of radiation oncology, biology, physics. 1986;12(8):1335-1337.

52. Bush R. S., Jenkin R D, Allt W E, Beale F A, Bean H, Dembo A J and Pringle J F. Definitive evidence for hypoxic cells influencing cure in cancer therapy. The British journal of cancer. Supplement.

1978;37(3):302-306.

53. Degner F. L. and Sutherland R M. Theoretical evaluation of

expected changes in oxygenation of tumors associated with different

hemoglobin levels. International journal of radiation oncology,

biology, physics. 1986;12(8):1291-1294.

54. Adams G. E. Radiosensitizers: a conference preview. International journal of radiation oncology, biology, physics.

1984;10(8):1181-1184.

55. Phillips T. L., Wasserman T H, Johnson R J, Levin V A and

VanRaalte G. Final report on the United States Phase I Clinical Trial of the hypoxic cell radiosensitizer, misonidazole (Ro-07-0582; NSC

#261037). Cancer. 1981;48(8):1697-1704.

56. Adams G. E. Hypoxia-mediated drugs for radiation and chemotherapy. Cancer. 1981;48(3):696-707.

57. Rauth A. M. and Kaufman K. In vivo testing of hypoxic radiosensitizers using the KHT murine tumour assayed by the lung-colony technique. The British journal of radiology.

1975;48(567):209-220.

58. Pradier O., Eberlein K, Weiss E, Jackel M C and Hess C F.

Radiotherapy combined with simultaneous chemotherapy with

mitomycin-C and 5-fluorouracil for inoperable head and neck cancer.

The British journal of radiology. 2001;74(880):368-374.

59. Harrison L. B., Chadha M, Hill R J, Hu K and Shasha D. Impact of tumor hypoxia and anemia on radiation therapy outcomes. The oncologist. 2002;7(6):492-508.

60. Dische S., Saunders M I, Flockhart I R, Lee M E and Anderson P.

Misonidazole-a drug for trial in radiotherapy and oncology.

International journal of radiation oncology, biology, physics.

1979;5(6):851-860.

61. Wasserman T. H., Phillips T L, Johnson R J, Gomer C J, Lawrence

G A, Sadee W, Marques R A, Levin V A and VanRaalte G. Initial

United States clinical and pharmacologic evaluation of misonidazole

(Ro-07-0582), an hypoxic cell radiosensitizer. International journal

of radiation oncology, biology, physics. 1979;5(6):775-786.

62. Benade L., Howard T and Burk D. Synergistic killing of Ehrlich ascites carcinoma cells by ascorbate and 3-amino-1,2,4,-triazole.

Oncology. 1969;23(1):33-43.

63. Josephy P. D., Palcic B and Skarsgard L D. Ascorbate-enhanced cytotoxicity of misonidazole. Nature. 1978;271(5643):370-372.

64. Urtasun R., Band P, Chapman J D, Feldstein M L, Mielke B and Fryer C. Radiation and high-dose metronidazole in supratentorial glioblastomas. The New England journal of medicine.

1976;294(25):1364-1367.

65. Beard C. J., Coleman C. N. and Kinsella T. J. Radiation Sensitizers.

In: V. T. DeVita, S. Hellman and S. A. Rosenberg. Cancer:

Principles and Practice of Oncology, 4th Edition. 1993. 2701-2713.

66. Kinsella T. J., Mitchell J B, Russo A, Morstyn G and Glatstein E.

The use of halogenated thymidine analogs as clinical

radiosensitizers: rationale, current status, and future prospects:

non-hypoxic cell sensitizers. International journal of radiation oncology, biology, physics. 1984;10(8):1399-1406.

67. Krook J. E., Moertel C G, Gunderson L L, Wieand H S, Collins R T, Beart R W, Kubista T P, Poon M A, Meyers W C and Mailliard J A.

Effective surgical adjuvant therapy for high-risk rectal carcinoma.

The New England journal of medicine. 1991;324(11):709-715.

68. Sischy B., Doggett R L, Krall J M, Taylor D G, Sause W T, Lipsett J A and Seydel H G. Definitive irradiation and chemotherapy for radiosensitization in management of anal carcinoma: interim report on Radiation Therapy Oncology Group study no. 8314. Journal of the National Cancer Institute. 1989;81(11):850-856.

69. Naida J. D., Davis M A and Lawrence T S. The effect of activation of wild-type p53 function on fluoropyrimidine-mediated

radiosensitization. International journal of radiation oncology,

biology, physics. 1998;41(3):675-680.

70. Lawrence T. S., Davis M A, Tang H Y and Maybaum J.

Fluorodeoxyuridine-mediated cytotoxicity and radiosensitization require S phase progression. International journal of radiation biology. 1996;70(3):273-280.

71. Lawrence T. S., Tepper J E and Blackstock A W.

Fluoropyrimidine-Radiation Interactions in Cells and Tumors.

Seminars in radiation oncology. 1997;7(4):260-266.

72. Lawrence T. S., Chang E Y, Hahn T M and Shewach D S. Delayed radiosensitization of human colon carcinoma cells after a brief exposure to 2',2'-difluoro-2'-deoxycytidine (Gemcitabine). Clinical cancer research : an official journal of the American Association for Cancer Research. 1997;3(5):777-782.

73. Shewach D. S., Hahn T M, Chang E, Hertel L W and Lawrence T S.

Metabolism of 2',2'-difluoro-2'-deoxycytidine and radiation sensitization of human colon carcinoma cells. Cancer research.

1994;54(12):3218-3223.

74. Lawrence T. S., Chang E Y, Hahn T M, Hertel L W and Shewach D S. Radiosensitization of pancreatic cancer cells by

2',2'-difluoro-2'-deoxycytidine. International journal of radiation oncology, biology, physics. 1996;34(4):867-872.

75. Ostruszka L. J. and Shewach D S. The role of cell cycle progression in radiosensitization by 2',2'-difluoro-2'-deoxycytidine. Cancer research. 2000;60(21):6080-6088.

76. Shewach D. S., Hahn T M, Chang E, Hertel L W and Lawrence T S.

Metabolism of 2',2'-difluoro-2'-deoxycytidine and radiation sensitization of human colon carcinoma cells. Cancer research.

1994;54(12):3218-3223.

77. Wachters F M, Kampinga H H, Van Putten JWG. Gemcitabine selectively targets homologous recombination mediated DNA double strand break repair. Proc Am Assoc Can Res. 2002. 43:149

78. Fields M. T., Eisbruch A, Normolle D, Orfali A, Davis M A, Pu A T and Lawrence T S. Radiosensitization produced in vivo by once- vs.

twice-weekly 2'2'-difluoro-2'-deoxycytidine (gemcitabine).

International journal of radiation oncology, biology, physics.

2000;47(3):785-791.

79. Lawrence T. S., Blackstock A W and McGinn C. The mechanism of action of radiosensitization of conventional chemotherapeutic agents.

Seminars in radiation oncology. 2003;13(1):13-21.

80. Amorino G. P., Freeman M L, Carbone D P, Lebwohl D E and Choy H. Radiopotentiation by the oral platinum agent, JM216: role of repair inhibition. International journal of radiation oncology, biology, physics. 1999;44(2):399-405.

81. Servidei T., Ferlini C, Riccardi A, Meco D, Scambia G, Segni G, Manzotti C and Riccardi R. The novel trinuclear platinum complex BBR3464 induces a cellular response different from cisplatin.

European journal of cancer (Oxford, England : 1990).

2001;37(7):930-938.

82. Moreland N. J., Illand M, Kim Y T, Paul J and Brown R.

Modulation of drug resistance mediated by loss of mismatch repair by the DNA polymerase inhibitor aphidicolin. Cancer research.

1999;59(9):2102-2106.

83. Woynarowski J. M., Chapman W G, Napier C, Herzig M C and Juniewicz P. Sequence- and region-specificity of oxaliplatin adducts in naked and cellular DNA. Molecular pharmacology.

1998;54(5):770-777.

84. Mamenta E. L., Poma E E, Kaufmann W K, Delmastro D A, Grady

H L and Chaney S G. Enhanced replicative bypass of platinum-DNA adducts in cisplatin-resistant human ovarian carcinoma cell lines.

Cancer research. 1994;54(13):3500-3505.

85. Meijer L. Chemical inhibitors of cyclin-dependent kinases. Trends in cell biology. 1996;6(10):393-397.

86. Havlicek L., Hanus J, Vesely J, Leclerc S, Meijer L, Shaw G and Strnad M. Cytokinin-derived cyclin-dependent kinase inhibitors:

synthesis and cdc2 inhibitory activity of olomoucine and related compounds. Journal of medicinal chemistry. 1997;40(4):408-412.

87. Mgbonyebi O. P., Russo J and Russo I H. Roscovitine induces cell death and morphological changes indicative of apoptosis in

MDA-MB-231 breast cancer cells. Cancer research.

1999;59(8):1903-1910.

88. Mgbonyebi O. P., Russo J and Russo I H. Roscovitine inhibits the proliferative activity of immortal and neoplastic human breast epithelial cells. Anticancer Research. 1998;18(2A):751-755.

89. Meijer L., Borgne A, Mulner O, Chong J P, Blow J J, Inagaki N, Inagaki M, Delcros J G and Moulinoux J P. Biochemical and

cellular effects of roscovitine, a potent and selective inhibitor of the cyclin-dependent kinases cdc2, cdk2 and cdk5. European journal of biochemistry / FEBS. 1997;243(1-2):527-536.

90. De Azevedo W. F., Leclerc S, Meijer L, Havlicek L, Strnad M and Kim S H. Inhibition of cyclin-dependent kinases by purine

analogues: crystal structure of human cdk2 complexed with roscovitine. European journal of biochemistry / FEBS.

1997;243(1-2):518-526.

91. Rudolph B., Saffrich R, Zwicker J, Henglein B, Muller R, Ansorge

W and Eilers M. Activation of cyclin-dependent kinases by Myc

mediates induction of cyclin A, but not apoptosis. The EMBO

journal. 1996;15(12):3065-3076.

92. Wani M. C., Taylor H L, Wall M E, Coggon P and McPhail A T.

Plant antitumor agents. VI. The isolation and structure of taxol, a novel antileukemic and antitumor agent from Taxus brevifolia.

Journal of the American Chemical Society. 1971;93(9):2325-2327.

93. Schiff P. B. and Horwitz S B. Taxol stabilizes microtubules in mouse fibroblast cells. Proceedings of the National Academy of Sciences of the United States of America. 1980;77(3):1561-1565.

94. Manfredi J. J. and Horwitz S B. Taxol: an antimitotic agent with a new mechanism of action. Pharmacology & therapeutics.

1984;25(1):83-125.

95. Tishler R. B., Geard C R, Hall E J and Schiff P B. Taxol sensitizes human astrocytoma cells to radiation. Cancer research.

1992;52(12):3495-3497.

96. Liebmann J., Cook J A, Fisher J, Teague D and Mitchell J B.

Changes in radiation survival curve parameters in human tumor and rodent cells exposed to paclitaxel (Taxol). International journal of radiation oncology, biology, physics. 1994;29(3):559-564.

97. Hei T. K., Piao C Q, Geard C R and Hall E J. Taxol and ionizing radiation: interaction and mechanisms. International journal of radiation oncology, biology, physics. 1994;29(2):267-271.

98. Chendil D., Ranga R S, Meigooni D, Sathishkumar S and Ahmed M M. Curcumin confers radiosensitizing effect in prostate cancer cell line PC-3. Oncogene. 2004;23(8):1599-1607.

99. Kumar A., Rao A R and Kimura H. Radiosensitizing effects of neem (Azadirachta indica) oil. Phytotherapy research : PTR.

2002;16(1):74-77.

100. Murayama C., Nagao Y, Sano S, Ochiai M, Fuji K, Fujita E and Mori T. Effect of oridonin, a Rabdosia diterpenoid, on

radiosensitization with misonidazole. Experientia.

1987;43(11-12):1221-1223.

101. 張紅軍 袁勝利 丁愛萍 修元德 于洪升 雷煒 張昌義 司玉峰 馬藺子素放射增敏作用的臨床研究 臨床腫瘤學雜誌 2000 年 6 月第 5 卷第 2 期 122-123

102. 韓俊慶 王興文 王瑜 李冠貞 韓玉萍 楊哲 顏廷秀 洪士強 鶴 草酚對肺腺癌放射增敏的臨床前瞻性研究 中華放射醫學與防護 雜誌 2003 年 10 月第 23 卷第 5 期 355-357

103. 張居馨 王士賢 張富庚 張玉華 青蒿琥酯對人宮頸癌 HeLa 細胞 的乏氧殺傷和輻射增敏作用初探 癌症 2001, 20(12):1363-1366

104. 呂長興 郭慶敏 程炳權 何劍利 枸杞多糖對急性乏氧 Lewis 肺 癌放射增敏效應的研究 中華放射腫瘤學雜誌 1995 年 9 月第 4 卷第 3 期 182-183

105. 胡笑克 李毓 吳棣華 胡祖光 梁昌盛 薏苡仁酯對人鼻咽癌細胞 的放射增敏作用 中山醫科大學學報 2000,21(5):334-336

106. 祈超 闞全程 賀會江 王秀菊 楊道科 蝎毒放射增敏、熱增敏研 究 醫師進修雜誌 2000,Vol.23,No.7 30-32

107. 劉妙玲 鄒麗娟 崔桂敏 苑蘭惠 王萍 張彥喬 欖香烯乳放射增 敏骨轉移癌 60 例臨床研究 中國腫瘤臨床 2001 年第 28 卷第 12 期 889-891

108. Ueda S., Nakamura H, Masutani H, Sasada T, Takabayashi A, Yamaoka Y and Yodoi J. Baicalin induces apoptosis via

mitochondrial pathway as prooxidant. Molecular immunology.

2002;38(10):781-791.

109. Inoue T. and Jackson E K. Strong antiproliferative effects of

baicalein in cultured rat hepatic stellate cells. European journal of pharmacology. 1999;378(1):129-135.

110. Jacobson M. D., Weil M and Raff M C. Programmed cell death in animal development. Cell. 1997;88(3):347-354.

111. PAINTER R. B. and ROBERTSON J S. Effect of irradiation and theory of role of mitotic delay on the time course of labeling of HeLa S3 cells with tritiated thymidine. Radiation research.

1959;11206-217.

112. Leeper D. B., Schneiderman M H and Dewey W C.

Radiation-induced division delay in synchronized Chinese hamster ovary cells in monolayer culture. Radiation research.

1972;50(2):401-417.

113. Harris C. C. Structure and function of the p53 tumor suppressor gene: clues for rational cancer therapeutic strategies. Journal of the National Cancer Institute. 1996;88(20):1442-1455.

114. Kastan M. B., Canman C E and Leonard C J. P53, cell cycle control and apoptosis: implications for cancer. Cancer and metastasis

reviews. 1995;14(1):3-15.

115. Bunz F., Dutriaux A, Lengauer C, Waldman T, Zhou S, Brown J P, Sedivy J M, Kinzler K W and Vogelstein B. Requirement for p53 and p21 to sustain G2 arrest after DNA damage. Science.

1998;282(5393):1497-1501.

116. Walters R. A., Gurley L R and Tobey R A. Effects of caffeine on radiation-induced phenomena associated with cell-cycle traverse of mammalian cells. Biophysical journal. 1974;14(2):99-118.

117. Lau C. C. and Pardee A B. Mechanism by which caffeine potentiates

lethality of nitrogen mustard. Proceedings of the National Academy

of Sciences of the United States of America. 1982;79(9):2942-2946.

118. Valenzuela M. T., Mateos S, Ruiz de Almodovar J M and McMillan T J. Variation in sensitizing effect of caffeine in human tumour cell lines after gamma-irradiation. Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

2000;54(3):261-271.

119. Bhattacharjee S. B., Bhattacharyya N and Chatterjee S. Influence of caffeine on X-ray-induced killing and mutation in V79 cells.

Radiation research. 1987;109(2):310-318.

120. Musk S. R. and Steel G G. Override of the radiation-induced mitotic block in human tumour cells by methylxanthines and its relationship to the potentiation of cytotoxicity. International journal of radiation biology. 1990;57(6):1105-1112.

121. Teicher B. A., Holden S A, Herman T S, Epelbaum R, Pardee A B and Dezube B. Efficacy of pentoxifylline as a modulator of

alkylating agent activity in vitro and in vivo. Anticancer Research.

1991;11(4):1555-1560.

122. Majno G. and Joris I. Apoptosis, oncosis, and necrosis. An overview of cell death. American Journal of Pathology. 1995;146(1):3-15.

123. Kerr J. F., Winterford C M and Harmon B V. Apoptosis. Its significance in cancer and cancer therapy. Cancer.

1994;73(8):2013-2026.

124. Sinclair W. K. Cyclic x-ray responses in mammalian cells in vitro.

Radiation research. 1968;33(3):620-643.

125. Maggiorella L., Deutsch E, Frascogna V, Chavaudra N, Jeanson L,

Milliat F, Eschwege F and Bourhis J. Enhancement of radiation

response by roscovitine in human breast carcinoma in vitro and in

vivo. Cancer research. 2003;63(10):2513-2517.